EMG
BPMC icon

ETF Managers Group’s Blueprint Medicines BPMC Stock Holding History

ETF Managers Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,616
Closed -$202K – 694
2022
Q4 		$202K Buy
+4,616
New +$221K 0.01% 477

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ETF Managers Group's BPMC Position: Q1 2023 in Review

ETF Managers Group sold out of Blueprint Medicines (BPMC) in Q1 2023, closing a stake of 4,616 shares — an estimated $202K sold.

ETF Managers Group first reported a position in BPMC in Q4 2022 and held it in 1 quarter. The position peaked at $202K in Q4 2022. 214 funds tracked by Wall St. Rank hold BPMC as of Q1 2023.

  • ETF Managers Group reported no remaining Blueprint Medicines position as of Q1 2023 after selling out during the quarter.
  • ETF Managers Group sold 4,616 Blueprint Medicines shares in Q1 2023, an estimated $202K.
  • ETF Managers Group first reported a position in Blueprint Medicines in Q4 2022 and held it in 1 quarter.
  • ETF Managers Group's Blueprint Medicines position peaked at $202K in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.